Stemedica Initiating Phase IIb/III Clinical Trial for Patients with Chronic Ischemic Stroke

Stemedica Cell Technologies announced that it has initiated its “Phase IIb/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Efficacy, Safety, And Tolerability Of A Single Intravenous Injection Of Allogeneic Mesenchymal Stem Cells To Subjects With Ischemic Stroke”” under an existing US IND using its ischemic tolerant MSC product.